Human IL-10 Protein, premium grade
分子別名(Synonym)
CSIF,IL-10,IL10A,TGIF,B-TCGF,GVHDS,MGC126450,MGC126451,RP11-262N9.1,Interleukin-10
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-10, premium grade (IL0-H5219) is expressed from human 293 cells (HEK293). It contains AA Ser 19 - Asn 178 (Accession # P22301.1).
Predicted N-terminus: Ser 19
Human IL-10,premium級(jí)(IL0-H5219),專為臨床前階段設(shè)計(jì),具有與GMP人IL-10相同的活性和性能,可實(shí)現(xiàn)從臨床前開(kāi)發(fā)到臨床階段的無(wú)縫過(guò)渡。在原材料安全不是首要任務(wù)的早期開(kāi)發(fā)階段,premium級(jí)產(chǎn)品為GMP級(jí)產(chǎn)品提供了一種經(jīng)濟(jì)高效的替代品。通過(guò)在早期開(kāi)發(fā)階段使用Premium級(jí)產(chǎn)品,您可以輕松過(guò)渡到臨床和商業(yè)階段,而無(wú)需重新驗(yàn)證原材料和修改制造工藝。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 18.6 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留(Host Cell Protein)
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
無(wú)菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素-10(IL-10)也稱為人類細(xì)胞因子合成抑制因子(CSIF),是一種抗炎細(xì)胞因子。IL-10是一種免疫抑制細(xì)胞因子,由多種哺乳動(dòng)物細(xì)胞類型產(chǎn)生,包括巨噬細(xì)胞、單核細(xì)胞、T細(xì)胞、B細(xì)胞和角質(zhì)形成細(xì)胞。成熟的人IL-10與牛、犬、馬、貓、小鼠、綿羊、豬和大鼠IL-10具有72%-86%的氨基酸序列同一性。雖然人IL-10對(duì)小鼠細(xì)胞有活性,但小鼠IL-10不作用于人細(xì)胞。IL-10能夠抑制巨噬細(xì)胞和調(diào)節(jié)性T細(xì)胞等細(xì)胞產(chǎn)生的促炎細(xì)胞因子如IFN-γ、IL-2、IL-3、TNFα和GM-CSF的合成。它還顯示出抑制抗原呈遞細(xì)胞抗原呈遞能力的強(qiáng)大能力。然而,它對(duì)某些T細(xì)胞和肥大細(xì)胞也有刺激作用,并刺激B細(xì)胞成熟和抗體產(chǎn)生。敲除研究表明,白細(xì)胞介素-10/IL-10在腸道中起著重要的免疫調(diào)節(jié)作用??肆_恩病患者對(duì)使用產(chǎn)生重組白細(xì)胞介素-10的細(xì)菌進(jìn)行治療反應(yīng)良好,這表明白細(xì)胞介蛋白-10對(duì)抵消人體過(guò)度免疫的重要性。
關(guān)鍵字: IL-10;IL-10蛋白;IL-10重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。